Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Serum-Peel combo aims to fade dark spots and wrinkles

NCT ID NCT07429786

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding MELA B3 serum to a 35% glycolic acid peel works better than the peel alone for treating dark spots (melasma, post-acne marks, age spots) and signs of aging. About 80 adults aged 30-70 in Buenos Aires will use the treatments for 3 months. The goal is to see if the combination improves skin tone, fine lines, and firmness more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women and men 2. From 30 to 70 years of age (inclusive) 3. Good general health 4. With any type of phototype 5. Hyperpigmentation condition with average darkness \> 3: 1. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2) 2. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face 3. Solar lentigo (SL) with a pigmentation score\>5 6. Willingness to protect oneself from the sun as much as possible for the duration of the study 7. Willingness to avoid contraindicated products (irritants, other depigmenting agents) 8. Signing of written informed consent Exclusion Criteria: 1. Pregnant, breastfeeding or with pregnancy plans. 2. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier). 3. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit. 4. Active acne with 10 or more inflammatory lesions. 5. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth. 6. Participant using irritating products (require a washout period of at least 2 weeks). 7. Use of medications that may induce melasma, such as antiepileptics (requires a washout period of 1 month). 8. Use of other products with depigmenting activity (requires a washout period of 1 month). 9. Other facial dermatoses or known photosensitivity, or a pre-existing or latent dermatologic health condition and/or disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that, in the judgment of the investigator, are considered inappropriate for participation or may interfere with study results. 10. Topical treatments applied to the face (requires a 2-week washout period). 11. Scheduled facial procedures during the course of the study. 12. Participants undergoing phototherapy (requires a 1-month washout period). 13. Known hypersensitivity to study products. 14. History of laser resurfacing procedures, intense pulsed light, facial radiofrequency, deep peeling, facial mesotherapy with tranexamic acid, botulinum toxin or dermal filler injections, or cosmetic procedures on the face within 6 months prior to the start of the study. 15. Facial treatment with microdermabrasion within 6 weeks prior to study entry. 16. Persons with visible tanning, scars, moles, excessive hair or other dermal conditions on the face that, in the judgment of the investigator, may influence the results of the study. 17. History of skin cancer, immunosuppression or immunodeficiency disorders (including HIV infection or AIDS), or current use of immunosuppressive drugs. 18. Uncontrolled disease such as asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism. Persons with multiple health conditions may be excluded, even if controlled by diet or medication. 19. Participation in another clinical trial within one week prior to entering this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperpigmentation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.